In Vivo Proof-of-Concept Studies for Systemically Delivered siRNA Therapeutics Using Advanced LNP Platforms

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

In Vivo Proof-of-Concept Studies for Systemically Delivered siRNA Therapeutics Using Advanced LNP Platforms

In Vivo Proof-of-Concept for siRNA-LNP Therapeutics

CELL & GENE | RNA | BIOLOGICS

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

An effective in vivo proof-of-concept (POC) study for a systemically delivered siRNA therapeutic is defined by precise, reproducible data on biodistribution, target engagement, and preliminary safety. Our approach moves beyond standardized templates, developing tailored in vivo study designs that address the specific biology of your lipid nanoparticle (LNP) platform and siRNA payload. This process generates the decision-making data required to select a lead candidate and commit to a full IND-enabling program, minimizing clinical risk from the earliest stages.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Frequently Asked Questions

    What are the primary endpoints for an in vivo siRNA-LNP POC study?

    The core endpoints are pharmacokinetics (PK) to assess LNP and payload stability, pharmacodynamics (PD) to confirm target mRNA knockdown in relevant tissues, and comprehensive biodistribution analysis to quantify delivery to both target and non-target organs. These are supplemented with clinical observations and terminal histology for an early assessment of the safety profile.

    How do you select the appropriate animal model for RNA therapeutics?

    Model selection is driven by the therapeutic target’s biology and the LNP’s mechanism. We evaluate species for sequence homology of the target gene and for an immune system that appropriately reflects the human response to the LNP platform. For certain programs, this necessitates the use of nonhuman primate (NHP) models to generate the most translationally relevant data.

    What defines a successful proof-of-concept for an LNP-delivered payload?

    Success is characterized by a clear correlation between dose, exposure, and durable target knockdown in the intended tissue, coupled with a well-tolerated safety profile and minimal non-target tissue biodistribution. The data must be robust enough to confidently predict the therapeutic window for future IND-enabling toxicology studies.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

A Tailored Preclinical Strategy for Systemic siRNA Delivery

A standard, one-size-fits-all preclinical testing template does not exist for RNA therapeutics. The efficacy and safety of a systemically administered siRNA are inextricably linked to the lipid nanoparticle delivery vehicle. A successful in vivo POC study requires a data-driven strategy that evaluates the entire therapeutic construct: the LNP and its payload.

Our scientific approach focuses on answering the fundamental questions that determine a program’s viability. We design studies to precisely measure how the LNP protects the siRNA in circulation, facilitates cellular uptake in the target tissue, and enables escape for functional gene silencing, all while characterizing any potential immune stimulation or non-target effects.

Core In Vivo Endpoints for LNP-Delivered siRNA

Generating a complete dataset is foundational to de-risking a candidate before advancing to GxP-compliant studies. Our POC studies are designed to provide clear, actionable intelligence across several key domains.

  • Pharmacokinetics (PK): Characterization of the LNP and siRNA payload in circulation to determine stability and clearance rates.

  • Biodistribution: Quantitative assessment of tissue distribution to confirm delivery to the target organ and identify potential accumulation in non-target tissues like the spleen or liver.

  • Pharmacodynamics (PD): Direct measurement of target mRNA knockdown and subsequent protein reduction in tissues to establish a dose-response relationship and duration of effect.

  • Early Safety Assessment: Daily clinical observations, serum chemistry, and a focused terminal histology review to identify any early safety signals.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Translating Foundational Research into Clinical Readiness

The path from candidate to IND-enabling studies requires a deep understanding of translational biology. Insights from foundational research confirm the importance of verifying functional outcomes in vivo to ensure the data is relevant for human clinical development (PMID: 21628398). This principle is central to our study designs.

Demonstrating stable and functional target engagement within a relevant biological system provides the confidence needed to advance a therapeutic candidate (PMID: 14577924). This is how we support an 18-24 month timeline to get candidates to IND. While the Franklin Biolabs brand launched in 2024, our scientific leadership has maintained a 100% successful IND rate for programs under our guidance since 2019.

Animal Welfare and Model Integration

Our commitment to animal welfare is a core component of our scientific operations. We are an AAALAC accredited facility, strictly adhering to USDA guidelines and the 3Rs Principle of Replacement, Reduction, and Refinement in all studies conducted within our >100,000 sq ft facility. For programs requiring the most translationally relevant data, we have extensive experience with nonhuman primate (NHP) models, ensuring the highest standards of care and ethical conduct.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

Technical Visualization: siRNA-LNP In Vivo Proof-of-Concept Workflow

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities